Drug intelligence / Profile preview

Sail Malaria eRNA Antibody

Development stage: Preclinical
Lead developer: Sail Biomedicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sail Malaria eRNA Antibody is an investigational RNA-based therapeutic being developed by Sail Biomedicines in collaboration with the Bill & Melinda Gates Foundation. The program utilizes Sail's proprietary "Endless RNA" (eRNA) technology—a circular, non-coding RNA platform designed for high stability and prolonged protein expression compared to traditional linear mRNA. This specific candidate is engineered to encode a potent monoclonal antibody targeting the malaria parasite (*Plasmodium falciparum*). Intended for systemic delivery via intravenous (IV) administration, the eRNA instructs the patient's own cells to produce and secrete the neutralizing antibody. This approach aims to provide durable passive immunization and long-term protection against malaria, potentially overcoming the half-life and manufacturing limitations associated with traditional protein-based monoclonal antibody injections.

Other names: Malaria antibody (Sail Biomedicines)Gates Foundation Malaria Antibody Programmalaria antibody-Gates Foundation-antibody-IV-Malaria

Beyond the preview

Go deeper on Sail Malaria eRNA Antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sail Malaria eRNA Antibody.

Explore the full profile